Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: MOLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.67
1 Year Target Price $10.67
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.41% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 150.34M USD | Price to earnings Ratio - | 1Y Target Price 10.67 |
Price to earnings Ratio - | 1Y Target Price 10.67 | ||
Volume (30-day avg) 4 | Beta 0.56 | 52 Weeks Range 3.36 - 5.99 | Updated Date 12/2/2025 |
52 Weeks Range 3.36 - 5.99 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -51.42% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value 20738106 | Price to Sales(TTM) 199.56 |
Enterprise Value 20738106 | Price to Sales(TTM) 199.56 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 37399152 | Shares Floating 17489339 |
Shares Outstanding 37399152 | Shares Floating 17489339 | ||
Percent Insiders - | Percent Institutions 9.58 |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG ADR was founded in 2004 in Zurich, Switzerland. It focuses on developing DARPin therapeutics, a novel class of protein therapeutics. The company has evolved through various partnerships and clinical trials to advance its pipeline.
Core Business Areas
- DARPin Therapeutics Development: Development and commercialization of DARPin therapeutics for oncology and other diseases.
- Partnerships and Licensing: Collaboration with pharmaceutical companies for the development and commercialization of DARPin-based therapies.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceuticals. Its organizational structure includes research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- MP0420 (Ensovibep): A DARPin therapeutic targeting SARS-CoV-2. It was co-developed with Novartis. As of now, it has been sold and there is no available information on any potential competitors.
- Abicipar: Abicipar is not a Molecular Partners AG ADR product. It was developed by Allergan (now part of AbbVie). Molecular Partners was the technology provider. Allergan and not Molecular Partners has primary responsibility for this product.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the market for targeted therapeutics, is highly competitive and innovative. DARPin technology aims to address unmet needs in areas like oncology and immunology.
Positioning
Molecular Partners AG ADR is positioned as an innovator in protein therapeutics with its DARPin technology. Its competitive advantage lies in the potential for multi-specific targeting and improved drug properties.
Total Addressable Market (TAM)
The TAM for targeted protein therapeutics is substantial, estimated in billions of dollars annually. Molecular Partners AG ADR aims to capture a share of this market through its pipeline and partnerships.
Upturn SWOT Analysis
Strengths
- Novel DARPin technology
- Strategic partnerships with major pharmaceutical companies
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Dependence on partnerships for commercialization
- High research and development costs
- Clinical trial risks
Opportunities
- Expansion of DARPin technology into new therapeutic areas
- Potential for breakthrough therapies in oncology
- Increasing demand for targeted therapeutics
- Further strategic collaborations
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- LLY
Competitive Landscape
Molecular Partners AG ADR faces competition from established pharmaceutical companies with broader portfolios. Its advantage lies in its novel DARPin technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by partnerships and clinical trial progress.
Future Projections: Future growth depends on the success of its pipeline and continued collaborations.
Recent Initiatives: Recent strategic initiatives may include new partnerships, clinical trial updates, and expansion of its DARPin platform.
Summary
Molecular Partners AG ADR is a biotechnology company with a novel DARPin technology platform. They have partnerships which provide revenue, but their commercial success depends on clinical trial outcomes and navigating regulatory hurdles. They need to continue to develop their pipeline to overcome these threats. The company has a novel tech so it is in a position to capitalize on demand for targeted therapeutics.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Financial news sources
- Analyst reports
- SEC filings (when applicable)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | |
Full time employees 158 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.